Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Researchers receive $3M R01 award to test new approach to treating brain tumors

With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.

30 Aug 2013

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy, an international team lead by researchers at The University of Texas MD Anderson Cancer Center reported online today in the journal Cancer Cell.

30 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Researchers suggest new therapeutic target for brain tumor

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas — the most common form of brain tumor — suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

28 Aug 2013

Researchers find specific protein in nearly all high-grade meningiomas

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas -- the most common form of brain tumor -- suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

28 Aug 2013

Scanning technique reveals how brain tumor responds to drug administered

A new scanning technique developed by Danish and US researchers reveals how susceptible patients with aggressive brain cancer are to the drugs they receive. The research behind the ground-breaking technique has just been published in Nature Medicine.

26 Aug 2013

Stem cell therapy improves radiation-induced cognitive impairment

Patients receiving cranial irradiation treatment for brain cancer may find the treatment life-saving, but often suffer progressive and debilitating cognitive detriments, including spatial learning and memory deficits. The cognitive deficits are a contributing factor to the often significant adverse impacts on the surviving patients' quality of life after radiation therapy. In an effort to improve post-irradiation cognitive impairment, scientists at the University of California, Irvine, and colleagues at Neuralstem, Inc. (Rockville, MD), have transplanted fetal stem cells into laboratory animals with radiation-induced cognitive impairments and found that this led to a number of cognitive improvements.

23 Aug 2013

Evidence shows bevacizumab therapy improves survival in patients with glioblastoma

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.

20 Aug 2013

Phase II trial to investigate vaccine therapy combined with Avastin for patients with recurrent GBM

Northwestern Medicine- recently joined a landmark clinical trial to investigate if a vaccine made from a patient's own brain tumor is effective in slowing tumor progression and extending survival.

16 Aug 2013

Researchers suggest neural stem cells may regenerate after anti-cancer treatment

Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new Johns Hopkins research in mice suggests that neural stem cells, the body's source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like state to reproduce and generate new cells able to migrate, replace injured cells and potentially restore lost function.

13 Aug 2013

Study provides clues to improve treatment of neuroblastoma with suppressor gene

Loss of a gene required for stem cells in the brain to turn into neurons may underlie the most severe forms of neuroblastoma, a deadly childhood cancer of the nervous system, according to a Ludwig Cancer Research study.

13 Aug 2013

Researchers explore potential of neural stem cells to repair brain damage

Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new Johns Hopkins research in mice suggests that neural stem cells, the body’s source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like state to reproduce and generate new cells able to migrate, replace injured cells and potentially restore lost function.

13 Aug 2013

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.

12 Aug 2013

Understanding the movement of neurons sheds light on how cancer cells invade health tissues

The invasion of brain-tumor cells into surrounding tissue requires the same protein molecule that neurons need to migrate into position as they differentiate and mature, according to new research from the University of Illinois at Chicago College of Medicine and published August 7 in the online journal PLOS ONE.

8 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

Novocure uses NovoTTF therapy to treat first recurrent glioblastoma tumor patient

Novocure today announced that Dr. Tatsunori Okamaura, MD, Ph.D., of the Kashiwaba Neurosurgical Hospital in Sapporo, Japan has treated the first patient in Japan with alternating electric field therapy.

1 Aug 2013

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme.

30 Jul 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Brain Cancer News and Research

Further Reading

Researchers receive $3M R01 award to test new approach to treating brain tumors

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Researchers suggest new therapeutic target for brain tumor

Researchers find specific protein in nearly all high-grade meningiomas

Scanning technique reveals how brain tumor responds to drug administered

Stem cell therapy improves radiation-induced cognitive impairment

Evidence shows bevacizumab therapy improves survival in patients with glioblastoma

Phase II trial to investigate vaccine therapy combined with Avastin for patients with recurrent GBM

Researchers suggest neural stem cells may regenerate after anti-cancer treatment

Study provides clues to improve treatment of neuroblastoma with suppressor gene

Researchers explore potential of neural stem cells to repair brain damage

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Understanding the movement of neurons sheds light on how cancer cells invade health tissues

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

Novocure uses NovoTTF therapy to treat first recurrent glioblastoma tumor patient

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News